Patients with ICH admitted to any of 20 hospitals in a large integrated health care delivery system over a 10-year period

Survival to 30 days after ICH and discharge to home or inpatient rehabilitation facility

• Among patients hospitalized for ICH, inpatient statin users were more likely than nonusers to be alive 30 days after ICH (OR, 4.25 [95% CI, 3.46-5.23]; P < .001) and were more likely than nonusers to be discharged to their home or an acute rehabilitation facility (OR, 2.57 [95% CI, 2.16-3.06]; P < .001).
  
• Patients whose statin therapy was discontinued were less likely than statin users to survive to 30 days (OR, 0.16 [95% CI, 0.12-0.21]; P < .001) and were less likely than statin users to be discharged to their home or an acute rehabilitation facility (OR, 0.26 [95% CI, 0.20-0.35]; P < .001).

A literature search of Medline, Web of Science, and The Cochrane Library through January 25, 2012 was done and identified additional RCTs by reviewing reference lists of retrieved studies and prior meta-analyses. All randomized controlled trials of statin therapy that reported ICH or hemorrhagic stroke were included. The primary outcome variable was ICH.

• A total of 91,588 subjects were included in the active group and 91,215 in the control group.
  
• There was no significant difference in incidence of ICH observed in the active treatment group versus control (OR, 1.08; 95% CI, 0.88-1.32; P=0.47).
  
• ICH risk was not related to the degree of low-density lipoprotein reduction or achieved low-density lipoprotein cholesterol.
  
• Total stroke (OR, 0.84; 95% CI, 0.78-0.91; P<0.0001) and all-cause mortality (OR, 0.92; CI, 0.87-0.96; P=0.0007) were significantly reduced in the active therapy group.
  
• There was no evidence of publication bias.